Q4 2024 Earnings Call Transcript March 17, 2025 Quanterix Corporation misses on earnings expectations. Reported EPS is $-0.3 ...

Additionally, the Company launched the Simoa® PSD-95 Advantage PLUS Assay measuring postsynaptic density protein 95 (PSD-95), an essential component of synaptic signaling complexes, playing a ...

So with Simoa ONE, and we've been very focused from an assay perspective on expanding into immunology and oncology applications. So day one of our product launch, you're going to see immunology menu.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the ...

4 Detection methods for ischemic stroke-related biomarkers Currently, common diagnostic methods for stroke biomarkers in clinical practice include enzyme-linked immunosorbent assay (ELISA), ...

NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, recently set up on clinical-grade platforms. Serum GFAP and pTau181 were also ...